DGX vs. ONC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DGX and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DGX is a standard domestic listing, while ONC trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
Symbol | DGX | ONC |
---|---|---|
Company Name | Quest Diagnostics Incorporated | BeOne Medicines AG |
Country | United States | Switzerland |
GICS Sector | Health Care | Health Care |
GICS Industry | Health Care Providers & Services | Biotechnology |
Market Capitalization | 21.13 billion USD | 37.96 billion USD |
Exchange | NYSE | NasdaqGS |
Listing Date | December 17, 1996 | February 3, 2016 |
Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DGX and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
Symbol | DGX | ONC |
---|---|---|
5-Day Price Return | -1.79% | -0.90% |
13-Week Price Return | 1.53% | 32.50% |
26-Week Price Return | 9.68% | 41.02% |
52-Week Price Return | 17.28% | 20.61% |
Month-to-Date Return | -4.47% | 10.40% |
Year-to-Date Return | 20.69% | 90.60% |
10-Day Avg. Volume | 0.89M | 4.56M |
3-Month Avg. Volume | 0.94M | 4.05M |
3-Month Volatility | 24.64% | 51.09% |
Beta | 0.64 | 0.78 |
Profitability
Return on Equity (TTM)
DGX
13.70%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
DGX’s Return on Equity of 13.70% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
ONC
-6.58%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
ONC has a negative Return on Equity of -6.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DGX
9.03%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 9.03% places DGX in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
ONC
-5.04%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ONC has a negative Net Profit Margin of -5.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
DGX
14.02%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 14.02% places DGX in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ONC
-2.03%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ONC has a negative Operating Profit Margin of -2.03%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
Symbol | DGX | ONC |
---|---|---|
Return on Equity (TTM) | 13.70% | -6.58% |
Return on Assets (TTM) | 5.94% | -3.87% |
Net Profit Margin (TTM) | 9.03% | -5.04% |
Operating Profit Margin (TTM) | 14.02% | -2.03% |
Gross Profit Margin (TTM) | 33.23% | 85.37% |
Financial Strength
Current Ratio (MRQ)
DGX
1.09
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
DGX’s Current Ratio of 1.09 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
ONC
1.94
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ONC’s Current Ratio of 1.94 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DGX
0.78
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
DGX’s Debt-to-Equity Ratio of 0.78 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ONC
0.27
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
ONC’s Debt-to-Equity Ratio of 0.27 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DGX
7.42
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
DGX’s Interest Coverage Ratio of 7.42 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
ONC
-132.16
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
Symbol | DGX | ONC |
---|---|---|
Current Ratio (MRQ) | 1.09 | 1.94 |
Quick Ratio (MRQ) | 0.86 | 1.65 |
Debt-to-Equity Ratio (MRQ) | 0.78 | 0.27 |
Interest Coverage Ratio (TTM) | 7.42 | -132.16 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DGX
1.67%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Yield of 1.67% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
ONC
0.17%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC’s Dividend Yield of 0.17% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
DGX
36.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Payout Ratio of 36.00% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
ONC
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
Symbol | DGX | ONC |
---|---|---|
Dividend Yield (TTM) | 1.67% | 0.17% |
Dividend Payout Ratio (TTM) | 36.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DGX
21.61
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
DGX’s P/E Ratio of 21.61 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ONC
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for ONC is currently unavailable.
Price-to-Sales Ratio (TTM)
DGX
1.95
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
DGX’s P/S Ratio of 1.95 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
ONC
9.25
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ONC’s P/S Ratio of 9.25 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
DGX
2.77
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
DGX’s P/B Ratio of 2.77 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ONC
8.16
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
ONC’s P/B Ratio of 8.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
Symbol | DGX | ONC |
---|---|---|
Price-to-Earnings Ratio (TTM) | 21.61 | -- |
Price-to-Sales Ratio (TTM) | 1.95 | 9.25 |
Price-to-Book Ratio (MRQ) | 2.77 | 8.16 |
Price-to-Free Cash Flow Ratio (TTM) | 16.77 | 156.50 |